Research Reports Coverage on Healthcare Stocks -- Immune Pharma, Sanofi, Shire, and Universal Health Services

Sep 09, 2016, 08:05 ET from Chelmsford Park SA

NEW YORK, September 9, 2016 /PRNewswire/ -- redirects its attention to the Healthcare space, S&P healthcare sector has declined 3% in the past month due to political attacks. In the second quarter, however, the S&P Healthcare sector had the second highest earnings growth percentage of the major S&P sectors, up 7.5%, according to Thomson Reuters. Let us see where the following equities stand in the market today: Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Universal Health Services Inc. (NYSE: UHS). These stocks research reports can be downloaded now by simply registering for free at:

Immune Pharma  

New York headquartered Immune Pharmaceuticals Inc.'s stock finished Thursday's session 2.70% lower at $0.36. A total volume of 3.10 million shares was traded, which was above their three months average volume of 2.72 million shares. The Company's shares are trading below their 50-day moving average by 8.26%. Furthermore, shares of Immune Pharmaceuticals, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have a Relative Strength Index (RSI) of 45.66.

On September 7th, 2016, Immune Pharmaceuticals announced that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of its common stock at a fixed price of $0.50 per share, for gross proceeds of $2,000,000. The company noted that there are no warrants, no restrictive covenants, and no restrictions on use of proceeds. Your complete research report on IMNP can be retrieved for free at:


On Thursday, shares in Paris, France headquartered Sanofi ended the session at $40.09, up 1.24%. The stock recorded a trading volume of 2.79 million shares, which was higher than its three months average volume of 2.34 million shares. The Company's shares are trading 0.16% above their 200-day moving average. Moreover, shares of Sanofi, which researches, develops, manufactures, and markets various therapeutic solutions, have an RSI of 53.83.

On September 06th, 2016, Sanofi announced that it has successfully priced its offering of EUR 3 billion of notes across 3 tranches, EUR 1.0 billion Fixed Rate Notes, due January 2020, bearing interest at an annual rate of 0.0%. EUR 0.85 billion Fixed Rate Notes is due on September 2022, bearing interest at an annual rate of 0.0%. EUR 1.15 billion Fixed Rate Notes, due January 2027, bearing interest at an annual rate of 0.5%. The transaction enables the company to lower its average cost of debt and extend the average maturity of its debt. Sanofi intends to use the net proceeds of the offering for general corporate purposes.

On September 08th, 2016, research firm Berenberg upgraded the Company's stock rating from 'Hold' to 'Buy'. SNY free report is just a click away at:


Dublin, Ireland headquartered Shire PLC's stock ended yesterday's session 1.11% lower at $191.45 with a total volume of 405,664 shares traded. The Company's shares have advanced 4.15% in the previous three months. The stock is trading 4.90% above its 200-day moving average. Additionally, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 44.22.

On August 29th, 2016, Shire announced that Xiidra™ (lifitegrast ophthalmic solution) 5%, a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, is now available by prescription in the US. An estimated 16 million adults in the US are diagnosed with dry eye, a disease associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment. The US FDA approved Xiidra on July 11th, 2016. Sign up for your complimentary research report on SHPG at:

Universal Health Services  

At the close on Thursday, shares in King of Prussia, Pennsylvania headquartered Universal Health Services Inc. recorded a trading volume of 670,518 shares. The stock finished 0.53% lower at $121.55. The Company's shares have gained 1.98% on an YTD basis. The stock is trading below its 200-day moving average by 1.39%. Furthermore, shares of Universal Health Services, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers, have an RSI of 42.52.

On August 16th, 2016, Universal Health Services announced that it has completed the acquisition of Desert View Regional Medical Center, a twenty-five bed hospital in Pahrump, Nevada. This acquisition expands UHS's acute care operations in Nevada, which includes six acute care hospitals in Las Vegas and Northern Nevada Medical Center in Sparks, Nevada. Desert View Hospital is an independent, 72,650 square foot hospital providing vital care to the Pahrump community. Register for free on and download the latest research report on UHS at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA